#China #Suzhou #Peijia Medical #Neurointerventional #TAVR system

Peijia Medical Reports Impressive Half-Year Results for 2025

On August 22, 2025, Peijia Medical (9996.HK), a prominent player in the transcatheter valve and neurovascular intervention markets in China, announced its interim financial results for the first half of 2025. The report revealed a strong performance, marked by steady revenue growth and improved operational efficiencies across its business segments.

Sustained Revenue Growth

Peijia Medical reported revenue of RMB 353.4 million for the six months ending June 30, 2025, reflecting a 17.3% increase compared to the same period last year. The stability of revenue composition between transcatheter aortic valve replacement (TAVR) and neurointerventional products was notable, with 45.7% of revenue coming from TAVR-related products and 54.3% from neurointerventional products.

This growth in revenue was driven by a remarkable 24.0% increase in sales of TAVR products, totaling RMB 161.6 million. The increase was largely attributed to heightened market share within China and the strategic introduction of premium products. Similarly, neurointerventional product revenue grew by 12.2%, totaling RMB 191.8 million, spurred by deeper penetration in key areas and the successful introduction of the YonFlow® Flow Diverting Stent.

Improving Profitability and Operational Efficiency

Peijia Medical's focus on operational excellence and lean management allowed for significant enhancements in expense ratios, leading to improved profitability. The segment profit for the Neurointerventional Business surged by 42.4% to RMB 40.9 million, while the losses in the transcatheter valve therapeutic segment narrowed by 35.3% to RMB 76.1 million. Moreover, the net loss of the group's core business showed a dramatic reduction of 52.4%, down to RMB 30.7 million.

This operational advancement was complemented by an expansion of the hospital coverage for TAVR products, with a noteworthy increase of over 70%, reaching more than 720 medical institutions across China. This strategic move saw total implant volumes exceeding 2,050 units, an increase of 18.8%, which is notably higher than the overall market growth.

Major Milestones and Product Launches

One of the critical developments during this reporting phase was the first commercial profit achieved by the Transcatheter Valve Therapeutic Business, marking a significant milestone for Peijia Medical. The comprehensive product portfolio, which now includes TaurusOne®, TaurusElite®, and TaurusMax™, provides a diversified pricing strategy while maintaining stable average margins and expanding access to the marketplace. Clinical feedback for TaurusMax™, featuring innovative 3D-steering technology, has been overwhelmingly positive.

The research and development expenses reflected a reduction of 17.2%, attributed to the completion of pivotal trials, yet anticipated acceleration in trials of the HighLife® TSMVR system was noted. Administrative costs saw a slight increase of 2.8%, primarily due to depreciation linked to the company's new headquarters offsetting cost-saving measures across the organization.

Pipeline Advancements and Future Outlook

Peijia Medical is also poised for future innovations, successfully completing follow-up studies for three core pipeline products; TaurusTrio™, TaurusNXT®, and GeminiOne®. Regulatory applications for TaurusTrio™ were submitted in April 2025, with others scheduled for submission in the coming months.

In the Neurointerventional segment, the significant rise in the sales of the DCwire® Micro Guidewire was recorded, along with successful bids for several products in provincial volume-based procurement programs.

Dr. Yi Zhang, Chairman and CEO of Peijia Medical, stated, "The first half of 2025 was characterized by simultaneous revenue growth, improved efficiency, and cost reductions. We're thrilled with the achievement of our Transcatheter Valve Therapeutic Business's first commercial profit, a significant milestone for us. Our commitment to both innovation and operational excellence positions us well for sustained future growth.' engagement for stakeholders and patients alike."

Overall, Peijia Medical continues to solidify its role as a leader in the medical device landscape, with a focus on innovative solutions that can help transform patient care. The company's strategic vision and operational refinement fortify its pathway toward increased profitability and market leadership, creating compelling value for shareholders and stakeholders.

For more information about Peijia Medical and its innovative products, visit peijiamedical.com.